Helen Ho

Helen Ho's Title

Helen Ho currently serves as the Chief Business Officer (CBO), a pivotal role that leverages her extensive background in corporate development, strategic planning, and business operations. As CBO, she is responsible for steering the company’s overall business strategy, fostering key partnerships, and driving growth initiatives. Her role is integral in shaping the company's market positioning and ensuring sustainable development in a competitive industry landscape.

Helen Ho's Education and Expertise

Helen Ho holds a Ph.D. in Cell Biology from Yale University, one of the most prestigious institutions globally. Her research-intensive Ph.D. program endowed her with a deep understanding of cellular mechanisms and advanced scientific methodologies. Helen also earned a B.S. in Biochemistry from the University of California, Los Angeles (UCLA), which provided a strong foundation in biochemical principles and laboratory practices. This combination of advanced education in cell biology and biochemistry equips her with the expertise to navigate and lead in the biotechnology and pharmaceutical industries effectively.

Helen Ho's Background

Helen Ho's career trajectory is marked by significant roles in both corporate and consulting environments. Prior to her current role, she was the Vice President and Head of Corporate Development at TCR2 Therapeutics, where she played a crucial role in securing a $125M Series B crossover financing. At Agios Pharmaceuticals, Helen served as the Director of Business Development & Operations, where she was instrumental in the company’s IPO and the development of its Rare Genetic Disorders and Immuno-Oncology franchises. Additionally, her experience as a management consultant at L.E.K. Consulting, with stints in both Boston and Shanghai offices, provided her with a global perspective and strategic acumen.

Helen Ho's Achievements

One of Helen Ho's standout achievements was her leadership in securing a $125M Series B crossover financing for TCR2 Therapeutics. This milestone significantly enhanced the company's financial stability and growth potential. At Agios Pharmaceuticals, Helen was pivotal in the company's IPO, which marked a major milestone in its corporate journey. She also played a key role in building the company's Rare Genetic Disorders and Immuno-Oncology franchises, showcasing her capability to drive strategic initiatives and foster innovation. Her work has consistently demonstrated a commitment to advancing the frontiers of biotechnology and pharmaceuticals.